skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Additive competitive interaction of verapamil and quinidine at alpha-adrenergic receptors of isolated cardiac guinea pig myocytes and human platelets

Journal Article · · Life Sci.; (United States)

Recent clinical work has questioned the safety of a combined therapy of oral quinidine and intravenenous verapamil, because some patients were reported to react with severe hypotension probably due to drug interactions with vascular alpha-adrenergic receptors. In order to obtain further quantitative information on the underlying mechanism, the authors used the radioligands (/sup 3/H)-prazosin and (/sup 3/H)-yohimbine to perform binding studies on intact cells, with predominantly alpha-1 (isolated myocytes) or alpha-2 subtypes (human platelets) of adrenergic receptors. Their studies confirm that both verapamil and quinidine possess a distinct alpha-adrenergic receptor blocking activity and do not discriminate between the alpha-1 and alpha-2 subtype. Their interaction was competitive and in the presence of both drugs inhibition of radioligand binding was additive. The alpha-adrenergic blockade by verapamil was stereospecific as D-verapamil increased the dissociation constant of the radioligand to a much lesser degree than L-verapamil. The calcium channel blocker nitrendipine, a 1,4-dihydropyridine derivative, did not show any competition up to concentrations of 10 ..mu..mol/l. 26 references, 5 figures, 1 table.

Research Organization:
Universitaet Duesseldorf, Germany, F.R.
OSTI ID:
5515933
Journal Information:
Life Sci.; (United States), Vol. 42:6
Country of Publication:
United States
Language:
English